Skip to main content

Advertisement

SpringerLink
Log in

Subcutaneous Fungal Infections

  • Skin, Soft Tissue, Bone, and Joint Infections (N Safdar, Section Editor)
  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

Subcutaneous mycoses are common in tropical and subtropical regions of the world. These infections have multiple features in common, including similar epidemiology, mode of transmission, indolent chronic presentation with low potential for dissemination in immunocompetent hosts, and pyogranulomatous lesions on histopathology. Herein, we provide up-to-date epidemiologic, clinical, diagnostic, and therapeutic data for three important subcutaneous mycoses: chromoblastomycosis, mycetoma, and sporotrichosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. • Baddley JW, Dismukes WE. Chromoblastomycosis. In: Kauffman CA, Pappas PG, Sobel JD, Dismukes WE, editors. Essentials of clinical mycology. New York: Springer Press; 2011. p. 427–33. Exhaustive review of chromoblastomycosis.

    Chapter  Google Scholar 

  2. Ameen M. Chromoblastomycosis: clinical presentation and management. Clin Exp Dermatol. 2009;34(8):849–54.

    Article  PubMed  CAS  Google Scholar 

  3. Howles JK, Kennedy CB, Carvin WH, et al. Chromoblastomycosis: report of nine cases from a single area in Louisiana. Arch Dermatol Syphilol. 1954;69:83–90.

    Article  CAS  Google Scholar 

  4. Gardner JT, et al. Chromoblastomycosis in Texas: Report of four cases. Tex State J Med. 1964;60:913–7.

    CAS  Google Scholar 

  5. Silva JP, de Souza W, Rozental S. Chromoblastomycosis: a retrospective study of 325 cases on Amazonic Region (Brazil). Mycopathologia. 1998-1999;143(3):171–5.

    Article  Google Scholar 

  6. Minotto R, Verajao Bernardi CD, Mallmann, et al. Chromoblastomycosis: a review of 100 cases in the state of Rio Grande do Sul, Brazil. J Am Acad Dermatol. 2001;44:585–92.

    Article  PubMed  CAS  Google Scholar 

  7. Correia RT, Valente NY, Criado PR, et al. Chromoblastomycosis: study of 27 cases and review of medical literature. An Bras Dermatol. 2010;85(4):448–54.

    Article  PubMed  Google Scholar 

  8. Pretelt Mendoza J.: Cromomicosis. Aspectos epidemiolgicos. Analisis de 82 casos estudiados en el Centro Dermatologico “Ladislao de la Pascua” de 1956-1988. Dermatology Specialty Thesis, Universidad Nacional Autonoma de Mexico, 1989.

  9. Bonifaz A, Carrasco-Gerard E, Saúl A. Chromoblastomycosis: clinical and mycologic experience of 51 cases. Mycoses. 2001;44:1–7.

    Article  PubMed  CAS  Google Scholar 

  10. Esterre P, Andriantsimahavandy A, et al. Forty years of chromoblastomycosis in Madagascar: a review. Am J Trop Med Hyg. 1996;55:45–7.

    PubMed  CAS  Google Scholar 

  11. López Martínez R, Méndez Tovar LJ. Chromoblastomycosis. Clin Dermatol. 2007;25(2):188–94.

    Article  PubMed  Google Scholar 

  12. Guedes Salgado C, Pereirada Silva J, Picanco Diniz JA, et al. Isolation of Fonsecaea pedrosoi from thorns of Mimosa pudica, a probable natural source of chromoblastomycosis. Rev Inst Med Trop Sao Paulo. 2004;46:33–6.

    Google Scholar 

  13. Cardona-Castro N, Agudelo-Flórez P. Development of a chronic chromoblastomycosis model in immunocompetent mice. Med Mycol. 1999;37(2):81–3.

    PubMed  CAS  Google Scholar 

  14. Santos AL, Palmeira VF, Rozental S, et al. Biology and pathogenesis of Fonsecaea pedrosoi, the major etiologic agent of chromoblastomycosis. FEMS Microbiol Rev. 2007;31(5):570–91.

    Article  PubMed  CAS  Google Scholar 

  15. •• Salgado CG. Fungal x host interactions in Chromoblastomycosis: what we have learned from animal models and what is yet to be solved. Virulence. 2010;1(1):3–5. This review article summarizes our current understanding of the immune response against chromoblastomycosis derived from animal models.

    Article  PubMed  Google Scholar 

  16. •• Sousa MdaG, Reid DM, Schweighoffer E, et al. Restoration of pattern recognition receptor costimulation to treat chromoblastomycosis, a chronic fungal infection of the skin. Cell Host Microbe. 2011;9(5):436–43. Original article that underscores the importance of the innate immune response, pattern recognizition receptors and their potential therapeutic applications.

    Article  CAS  Google Scholar 

  17. Rozental S, Alviano CS, de Souza W. The in vitro susceptibility of Fonsecaea pedrosoi to activated macrophages. Mycopathologia. 1994;126:85–91.

    Article  PubMed  CAS  Google Scholar 

  18. Ahrens J, Graybill JR, Abishawl A, et al. Experimental murine chromomycosis mimicking chronic progressive human disease. Am J Trop Med Hyg. 1989;40(6):651–8.

    PubMed  CAS  Google Scholar 

  19. de Sousa Teixeira MG, Ghosn EE, Almeida SR. Absence of CD4+ T cells impairs host defence of mice infected with Fonsecaea pedrosoi. Scand J Immunol. 2006;64:595–600.

    Article  CAS  Google Scholar 

  20. Gimenes VMF, Sousa MG, et al. Cytokine and lymphocyte proliferation in patients with different clinical forms of chromoblasto-mycosis. Microbes Infect. 2005;7:708–13.

    Article  CAS  Google Scholar 

  21. Queiroz-Telles F, Esterre P, Perez-Blanco M, et al. Chromoblastomycosis: an overview of clinical manifestations, diagnosis and treatment. Med Mycol. 2009;47:3–15.

    Article  PubMed  Google Scholar 

  22. McGinnis MR. Chromoblastomycosis and phaeohyphomycosis: new concepts, diagnosis and mycology. J Am Acad Dermatol. 1983;8:1–16.

    Article  PubMed  CAS  Google Scholar 

  23. Ogawa MM, Alchorne MM, Barbieri A, et al. Lymphoscintigraphic analysis in chromoblastomycosis. Int J Dermatol. 2003;42:622–5.

    Article  PubMed  Google Scholar 

  24. Fukushiro R. Chromomycosis in Japan. Int J Dermatol. 1983;22:221–9.

    Article  PubMed  CAS  Google Scholar 

  25. Takase T, Baba T, Ueno K. Chromomycosis. A case with a widespread rash, lymph node metastasis and multiple subcutaneous nodules. Mycoses. 1988;31:343–52.

    Article  PubMed  CAS  Google Scholar 

  26. Wackym PA. Cutaneous chromomycosis in renal transplant recipients. Arch Intern Med. 1985;145:1036–7.

    Article  PubMed  CAS  Google Scholar 

  27. Carrion A. Chromoblastomycosis. Ann NY Acad Sci. 1950;50:1255–81.

    Article  PubMed  CAS  Google Scholar 

  28. Abliz P, Fukushima K, Takizawa K, et al. Specific oligonucleotide primers for identification of Cladophialophora carrionii, a causative agent of chromoblastomycosis. J Clin Microbiol. 2004;42(1):404–7.

    Article  PubMed  CAS  Google Scholar 

  29. de Andrade TS, Cury AE, de Castro LG, et al. Rapid identification of Fonsecaea by duplex polymerase chain reaction in isolates from patients with chromoblastomycosis. Diagn Microbiol Infect Dis. 2007;57(3):267–72.

    Article  PubMed  CAS  Google Scholar 

  30. Abliz P, Fukushima K, Takizawa K, et al. Rapid identification of the genus fonsecaea by PCR with specific oligonucleotide primers. J Clin Microbiol. 2003;41(2):873–6.

    Article  PubMed  CAS  Google Scholar 

  31. Bonifaz A, Paredes-Solis V, Saul A. Treating chromoblastomycosis with systemic antifungals. Expert Opin Pharmacother. 2004;5:247–54.

    Article  PubMed  CAS  Google Scholar 

  32. Ameen M. Managing Chromoblastomycosis. Trop Doct. 2010;40(2):65–7.

    Article  PubMed  Google Scholar 

  33. Esterre P, Queiroz-Telles F. Management of chromoblastomycosis: novel perspectives. Curr Opin Infect Dis. 2006;19(2):148–52.

    Article  PubMed  Google Scholar 

  34. Vitale RG, Perez-Blanco M, De Hoog GS. In vitro activity of antifungal drugs against Cladophialophora species associated with human chromoblastomycosis. Med Mycol. 2009;47(1):35–40.

    Article  PubMed  CAS  Google Scholar 

  35. Caligiorne RB, Resende MA, Melillo PH, et al. In vitro susceptibility of chromoblastomycosis and phaeohyphomycosis agents to antifungal drugs. Med Mycol. 1999;37(6):405–9.

    Article  PubMed  CAS  Google Scholar 

  36. Gupta AK, Taborda PR, Sanzovo AD. Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil. Med Mycol. 2002;40:529–34.

    PubMed  CAS  Google Scholar 

  37. • Bustamante B, Campos PE. Eumycetoma. In: Kauffman CA, Pappas PG, Sobel JD, Dismukes WE, editors. Essentials of clinical mycology. 2nd ed. New York: Springer Press; 2011. p. 415–25. Extensive review of Eumycetoma.

    Chapter  Google Scholar 

  38. Hospenthal DR. Agents of mycetoma. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7th ed. Philadelphia: Churchill Livingstone; 2009. p. 3281–5.

    Google Scholar 

  39. Green Jr WO, Adams TE. Mycetoma in the United States: a review and report of seven additional cases. Am J Clin Pathol. 1964;42:75–91.

    PubMed  Google Scholar 

  40. Bendl BJ, Mackey D, Al-Saati F, et al. Mycetoma in Saudi Arabia. J Trop Med Hyg. 1987;90(2):51–9.

    PubMed  CAS  Google Scholar 

  41. Develoux M, Audoin J, Treguer J, et al. Mycetoma in the Republic of Niger: clinical features and epidemiology. Am J Trop Med Hyg. 1988;38(2):386–90.

    PubMed  CAS  Google Scholar 

  42. Castro LG, Belda Júnior W, Salebian A, et al. Mycetoma: a retrospective study of 41 cases seen in São Paulo, Brazil, from 1978 to 1989. Mycoses. 1993;36(3–4):89–95.

    PubMed  CAS  Google Scholar 

  43. Khatri ML, Al-Halali HM, Fouad Khalid M, et al. Mycetoma in Yemen: clinicoepidemiologic and histopathologic study. Int J Dermatol. 2002;41(9):586–93.

    Article  PubMed  Google Scholar 

  44. Dieng MT, Sy MH, Diop BM, et al. Mycetoma: 130 cases. Ann Dermatol Venereol. 2003;130(1 Pt 1):16–9.

    PubMed  Google Scholar 

  45. Bakshi R, Mathur DR. Incidence and changing pattern of mycetoma in western Rajasthan. Indian J Pathol Microbiol. 2008;51(1):154–5.

    Article  PubMed  Google Scholar 

  46. Castro LG, Piquero-Casals J. Clinical and mycologic findings and therapeutic outcome of 27 mycetoma patients from São Paulo, Brazil. Int J Dermatol. 2008;47(2):160–3.

    Article  PubMed  Google Scholar 

  47. Padhi S, Uppin SG, Uppin MS, et al. Mycetoma in South India: retrospective analysis of 13 cases and description of two cases caused by unusual pathogens: Neoscytalidium dimidiatum and Aspergillus flavus. Int J Dermatol. 2010;49(11):1289–96.

    Article  PubMed  Google Scholar 

  48. Ahmed AO, van Leeuwen W, Fahal A, et al. Mycetoma caused by Madurella mycetomatis: a neglected infectious burden. Lancet Infect Dis. 2004;4(9):566–74.

    Article  PubMed  Google Scholar 

  49. van de Sande WW, Gorkink R, Simons G, et al. Genotyping of Madurella mycetomatis by selective amplification of restriction fragments (amplified fragment length polymorphism) and subtype correlation with geographical origin and lesion size. J Clin Microbiol. 2005;43(9):4349–56.

    Article  PubMed  CAS  Google Scholar 

  50. van de Sande WW, Janse DJ, Hira V, Goedhart H, et al. Translationally controlled tumor protein from Madurella mycetomatis, a marker for tumorous mycetoma progression. J Immunol. 2006;177(3):1997–2005.

    PubMed  Google Scholar 

  51. Mahgoub ES, Gumaa SA, El Hassan AM. Immunological status of mycetoma patients. Bull Soc Pathol Exot Filiales. 1977;70(1):48–54.

    PubMed  CAS  Google Scholar 

  52. Fahal AH, Sadig ME, Suliman SH, et al. Lack of association between ABO blood groups and Rh factor and the tendency to develop mycetoma. East Afr Med J. 1996;73(11):771.

    PubMed  CAS  Google Scholar 

  53. Fahal AH, el Toum EA, el Hassan AM, et al. The host tissue reaction to Madurella mycetomatis: new classification. J Med Vet Mycol. 1995;33:15.

    Article  PubMed  CAS  Google Scholar 

  54. van de Sande WW, Fahal A, Verbrugh H, van Belkum A. Polymorphisms in genes involved in innate immunity predispose toward mycetoma susceptibility. J Immunol. 2007;179:3065.

    PubMed  Google Scholar 

  55. Ameen M, Arenas R. Emerging therapeutic regimes for the management of mycetomas. Expert Opin Pharmacother. 2008;9(12):2077–85.

    Article  PubMed  CAS  Google Scholar 

  56. El Hag IA, Fahal AH, Gasim ET. Fine needle aspiration cytology of mycetoma. Acta Cytol. 1996;40(3):461–4.

    Article  PubMed  CAS  Google Scholar 

  57. Gabhane SK, Gangane N, Anshu A. Cytodiagnosis of eumycotic mycetoma: a case report. Acta Cytol. 2008;52(3):354–6.

    Article  PubMed  Google Scholar 

  58. Afroz N, Khan N, Siddiqui FA, et al. Eumycetoma versus actinomycetoma: Diagnosis on cytology. J Cytol. 2010;27(4):133–5.

    Article  PubMed  Google Scholar 

  59. Hemalata M, Prasad S, Venkatesh K, et al. Cytological diagnosis of actinomycosis and eumycetoma: a report of two cases. Diagn Cytopathol. 2010;38(12):918–20.

    Article  PubMed  Google Scholar 

  60. • Yousif BM, Fahal AH, Shakir MY. A new technique for the diagnosis of mycetoma using fixed blocks of aspirated material. Trans R Soc Trop Med Hyg. 2010;104(1):6–9. This article in together with the two previous references highlight new diagnostic methods for eumycetoma.

    Article  PubMed  CAS  Google Scholar 

  61. Ahmed AO, Mukhtar MM, Kools-Sijmons M, et al. Development of a species-specific PCR-restriction fragment length polymorphism analysis procedure for identification of Madurella mycetomatis. J Clin Microbiol. 1999;37(10):3175–8.

    PubMed  CAS  Google Scholar 

  62. Desnos-Ollivier M, Bretagne S, Dromer F, et al. Molecular identification of black-grain mycetoma agents. J Clin Microbiol. 2006;44(10):3517–23.

    Article  PubMed  CAS  Google Scholar 

  63. Czechowski J, Nork M, Haas D, et al. MR and other imaging methods in the investigation of mycetomas. Acta Radiol. 2001;42:24.

    Article  PubMed  CAS  Google Scholar 

  64. Sharif HS, Clark DC, Aabed MY, et al. Mycetoma: comparison of MR imaging with CT. Radiology. 1991;178:865.

    PubMed  CAS  Google Scholar 

  65. Welsh O, Salinas MC, Rodríguez MA. Treatment of eumycetoma and actinomycetoma. Curr Top Med Mycol. 1995;6:47.

    PubMed  CAS  Google Scholar 

  66. Mahgoub ES, Gumaa SA. Ketoconazole in the treatment of eumycetoma due to Madurella mycetomii. Trans R Soc Trop Med Hyg. 1984;78:376.

    Article  PubMed  CAS  Google Scholar 

  67. Venugopal PV, Venugopal TV, Ramakrishna ES, Ilavarasi S. Antimycotic susceptibility testing of agents of black grain eumycetoma. J Med Vet Mycol. 1993;31:161.

    Article  PubMed  CAS  Google Scholar 

  68. Smith EL, Kutbi S. Improvement of eumycetoma with itraconazole. J Am Acad Dermatol. 1997;34:279–80.

    Article  Google Scholar 

  69. •• Fahal AH, Rahman IA, El-Hassan AM, et al. The safety and efficacy of itraconazole for the treatment of patients with eumycetoma due to Madurella mycetomatis. Trans R Soc Trop Med Hyg. 2011;105(3):127–32. Small prospective study, evaluating the safety and efficacy of itraconazole for the treatment of M. mycetomatis eumycetoma.

    Article  PubMed  CAS  Google Scholar 

  70. Restrepo A. Treatment of tropical mycoses. J Am Acad Dermatol. 1994;31(3 Pt 2):S91–S102.

    Article  PubMed  CAS  Google Scholar 

  71. •• van Belkum A, Fahal AH, van de Sande WW. In vitro susceptibility of Madurella mycetomatis to posaconazole and terbinafine. Antimicrob Agents Chemother. 2011;55(4):1771–3. First to describe the in vitro susceptibility of M. mycetomatis to posaconazole and terbinafine using 24 clinical isolates.

    Article  PubMed  CAS  Google Scholar 

  72. Negroni R, Tobon A, Bustamante B, et al. Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Rev Inst Med Trop Sao Paulo. 2005;47(6):339–46.

    Article  PubMed  Google Scholar 

  73. Difonzo EM, Massi D, Vanzi L, et al. Madurella mycetomatis mycetoma treated successfully with oral posaconazole. J Chemother. 2011;23(4):243–4.

    PubMed  CAS  Google Scholar 

  74. Lacroix C, De Kerviler E, Morel P, et al. Madurella mycetomatis mycetoma treated successfully with oral voriconazole. Br J Dermatol. 2005;152:1067–8.

    Article  PubMed  CAS  Google Scholar 

  75. Loulergue P, Hot A, Dannaoui E, et al. Successful treatment of black-grain mycetoma with voriconazole. Am J Trop Med Hyg. 2006;75(6):1106–7.

    PubMed  Google Scholar 

  76. N'diaye B, Dieng MT, Perez A, et al. Clinical efficacy and safety of oral terbinafine in fungal mycetoma. Int J Dermatol. 2006;45(2):154–7.

    Article  PubMed  Google Scholar 

  77. •• van de Sande WW, Fahal AH, Bakker-Woudenberg IA, et al. Madurella mycetomatis is not susceptible to the echinocandin class of antifungal agents. Antimicrob Agents Chemother. 2010;54(6):2738–40. Original study showing the lack of in-vitro activity of the echinocandins against M. mycetomatis.

    Article  PubMed  CAS  Google Scholar 

  78. Porte L, Khatibi S, Hajj LE, et al. Scedosporium apiospermum mycetoma with bone involvement successfully treated with voriconazole. Trans R Soc Trop Med Hyg. 2006;100(9):891–4.

    Article  PubMed  CAS  Google Scholar 

  79. McGinnis MR, Pasarell L. In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications. J Clin Microbiol. 1998;36(8):2353.

    PubMed  CAS  Google Scholar 

  80. Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother. 2008;52(5):1743.

    Article  PubMed  CAS  Google Scholar 

  81. Schaenman JM, DiGiulio DB, Mirels LF, et al. Scedosporium apiospermum soft tissue infection successfully treated with voriconazole: potential pitfalls in the transition from intravenous to oral therapy. J Clin Microbiol. 2005;43(2):973–7.

    Article  PubMed  Google Scholar 

  82. Matsumoto Y, Oh-I T, Nagai A, et al. Case of cutaneous Scedosporium apiospermum infection successfully treated with voriconazole. J Dermatol. 2009;36(2):98–102.

    Article  PubMed  Google Scholar 

  83. •• Pappas PG. Sporotrichosis. In: Kauffman CA, Pappas PG, Sobel JD, Dismukes WE, editors. Essentials of clinical mycology. 2nd ed. New York: Springer Press; 2011. p. 387–97. Detailed review on S. schenckii, infection, clinical manifestations, diagnosis and treatment.

    Chapter  Google Scholar 

  84. • López-Romero E, Reyes-Montes MdelR, Pérez-Torres A, et al. Sporothrix schenckii complex and sporotrichosis, an emerging health problem. Future Microbiol. 2011;6(1):85–102. Thorough review of sporotrichosis, with a particular focus of the biology of S. schenkii.

    Article  PubMed  Google Scholar 

  85. Marimon R, Gené J, Cano J, et al. Molecular phylogeny of Sporothrix schenckii. J Clin Microbiol. 2006;44(9):3251–6.

    Article  PubMed  CAS  Google Scholar 

  86. Marimon R, Cano J, Gené J, et al. Sporothrix brasiliensis, S. globosa, and S. mexicana, three new Sporothrix species of clinical interest. J Clin Microbiol. 2007;45(10):3198–206.

    Article  PubMed  CAS  Google Scholar 

  87. D’Alessio DJ, Leavens LJ, Strumpf GB, Smith CD. An outbreak of sporotrichosis in Vermont associated with sphagnum moss as the source of infection. N Engl J Med. 1965;272:1054–8.

    Article  Google Scholar 

  88. Powell KE, Taylor A, Phillips BJ, et al. Cutaneous sporotrichosis in forestry workers: epidemic due to contaminated sphagnum moss. JAMA. 1978;240:232–5.

    Article  PubMed  CAS  Google Scholar 

  89. Centers for Disease Control. Sporotrichosis associated with Wisconsin sphagnum moss. MMWR. 1982;31:542–4.

    Google Scholar 

  90. Itoh M, Okamoto S, Kariya H. Survey of 200 cases of sporotrichosis. Dermatologica. 1986;172:209–13.

    Article  PubMed  CAS  Google Scholar 

  91. Dixon DM, Salkin IF, Duncan RA, et al. Isolation and characterization of Sporothrix schenckii from clinical and environmental sources associated with the largest US epidemic of sporotrichosis. J Clin Microbiol. 1991;29:1106–13.

    PubMed  CAS  Google Scholar 

  92. Coles FB, Schuchat A, Hibbs JR, et al. A multistate outbreak of sporotrichosis associated with sphagnum moss. Am J Epidemiol. 1992;136:475–87.

    PubMed  CAS  Google Scholar 

  93. Hajjeh R, McDonnell S, Reef S, et al. Outbreak of sporotrichosis among tree nursery workers. J Infect Dis. 1997;176:499–504.

    Article  PubMed  CAS  Google Scholar 

  94. Dooley DP, Bostic PS, Beckius ML. Spook house sporotrichosis. A point-source outbreak of cutaneous sporotrichosis from hay bale props in a Halloween haunted-house. Arch Intern Med. 1997;157:1885–7.

    Article  PubMed  CAS  Google Scholar 

  95. Barros MB, Schubach AO, Schubach TM, Wanke B, Lambert-Passos SR. An epidemic of sporotrichosis in Rio de Janeiro, Brazil: epidemiological aspects of a series of cases. Epidemiol Infect. 2008;136:1192–6.

    Article  PubMed  CAS  Google Scholar 

  96. Schubach A, Barros MB, Wanke B. Epidemic sporotrichosis. Curr Opin Infect Dis. 2008;21(2):129–33.

    Article  PubMed  Google Scholar 

  97. •• Madrid IM, Mattei A, Martins A, et al. Feline sporotrichosis in the southern region of rio grande do sul, Brazil: clinical, zoonotic and therapeutic aspects. Zoonoses Public Health. 2010;57(2):151–4. Original article addressing the epidemic of sporotrichosis in Brazil derived from zoonotic transmission of the disease from cats.

    Article  PubMed  CAS  Google Scholar 

  98. • Rees RK, Swartzberg JE. Feline-transmitted sporotrichosis: A case study from California. Dermatol Online J. 2011;17(6):2. Report of zoonotic transmission of sporotrichosis in the United States.

    PubMed  Google Scholar 

  99. Pluss JL, Opal SM. Pulmonary sporotrichosis: review of treatment and outcome. Medicine (Baltimore). 1986;65(3):143–53.

    CAS  Google Scholar 

  100. Pappas PG, Tellez I, Deep AE, et al. Sporotrichosis in Peru: description of an area of hyperendemicity. Clin Inf Dis. 2000;20:65–70.

    Article  Google Scholar 

  101. Fukushiro R. Epidemiology and ecology of sporotrichosis in Japan. Zbl Bakt Hyg A. 1984;257:228–33.

    CAS  Google Scholar 

  102. Ramos-e-Silva M, Vasconcelos C, Carneiro S, et al. Sporotrichosis. Clin Dermatol. 2007;25(2):181–7.

    Article  PubMed  Google Scholar 

  103. Smego Jr RA, Castiglia M, Asperilla MO. Lymphocutaneous syndrome. A review of non-sporothrix causes. Medicine (Baltimore). 1999;78(1):38–63.

    Article  Google Scholar 

  104. Mahlberg MJ, Patel R, Rosenman K, et al. Fixed cutaneous sporotrichosis. Dermatol Online J. 2009;15(8):5.

    PubMed  Google Scholar 

  105. Kauffman CA. Sporotrichosis. Clin Infect Dis. 1999 Aug;29(2):231–6.

  106. Yacobucci GN, Santilli MD. Sporotrichosis of the knee. A case report. Orthopedics 9:387–90

  107. Yao J, Penn RG, Ray S. Articular sporotrichosis. Clin Orthop. 1986;204:207–14.

    PubMed  Google Scholar 

  108. Appenzeller S, Amaral TN, Amstalden EMI, et al. Sporothrix schenckii infection presented as monoarthritis: report of two cases and review of the literature. Clin Rheumatol. 2006;25:926–8.

    Article  PubMed  Google Scholar 

  109. Chowdhary G, Weinstein A, Klein R, Mascarenhas BR. Sporotrichal arthritis. Ann Rheum Dis. 1991;50:112–4.

    Article  PubMed  CAS  Google Scholar 

  110. Atdjian M, Granda JL, Ingberg HO, et al. Systemic sporotrichosis polytenosynovitis with median and ulnar nerve entrapment. JAMA. 1980;243:1841–2.

    Article  PubMed  CAS  Google Scholar 

  111. Stratton CW, Lichtenstein KA, Lowenstein SR, Phelps DB, Reller LB. Granulomatous tenosynovitis and carpal tunnel syndrome caused by Sporothrix schenckii. Am J Med. 1981;71:161–4.

    Article  PubMed  CAS  Google Scholar 

  112. Schwartz DA. Sporothrix tenosynovitis – differential diagnosis of granulomatous inflammatory disease of the joints. J Rheumatol. 1989;16:550–3.

    PubMed  CAS  Google Scholar 

  113. Witherspoon CD, Kuhn F, Owens SD, et al. Endophthalmitis due to Sporothrix schenckii after penetrating ocular injury. Ann Ophthalmol. 1990 Oct;22(10):385–8.

  114. Curi AL, Félix S, Azevedo KM, Estrela R, et al. Retinal granuloma caused by Sporothrix schenckii. Am J Ophthalmol. 2003;136(1):205–7.

    Article  PubMed  Google Scholar 

  115. Schubach A, de Lima Barros MB, Schubach TM, et al. Primary conjunctival sporotrichosis: two cases from a zoonotic epidemic in Rio de Janeiro, Brazil. Cornea. 2005;24(4):491–3. Review.

    Article  PubMed  Google Scholar 

  116. Kashima T, Honma R, Kishi S, et al. Bulbar conjunctival sporotrichosis presenting as a salmon-pink tumor. Cornea. 2010;29(5):573–6.

    Article  PubMed  Google Scholar 

  117. Iyengar SS, Khan JA, Brusco M, et al. Cutaneous Sporothrix schenckii of the human eyelid. Ophthal Plast Reconstr Surg. 2010;26(4):305–6.

    Article  PubMed  Google Scholar 

  118. Heller HM, Fuhrer J. Disseminated sporotrichosis in patients with AIDS: case report and review of the literature. AIDS. 1991 Oct;5(10):1243–6.

  119. al-Tawfiq JA, Wools KK. Disseminated sporotrichosis and Sporothrix schenckii fungemia as the initial presentation of human immunodeficiency virus infection. Clin Infect Dis. 1998;26(6):1403–6.

    Article  PubMed  CAS  Google Scholar 

  120. Yelverton CB, Stetson CL, Bang RH, et al. Fatal sporotrichosis. Cutis. 2006 Oct;78(4):253–6.

  121. Zhang YQ, Xu XG, Zhang M, et al. Sporotrichosis: clinical and histopathological manifestations. Am J Dermatopathol. 2011;33(3):296–302.

    Article  PubMed  Google Scholar 

  122. •• Assi M, Lakkis IE, Wheat LJ. Cross-reactivity in the Histoplasma antigen enzyme immunoassay caused by sporotrichosis. Clin Vaccine Immunol. 2011;18(10):1781–2. Report of a case of false positive Histoplasma antigen enzyme immunoassay in a patient with pulmonary sporotrichosis.

    Article  PubMed  CAS  Google Scholar 

  123. Kauffman CA, Bustamante B, Chapman SW, et al. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45(10):1255–65.

    Article  PubMed  CAS  Google Scholar 

  124. Restrepo A, Robledo J, Gomez I, Tabares AM, Gutierrez R. Itraconazole therapy in lymphangitic and cutaneous sporotrichosis. Arch Dermatol. 1986;122:413–7.

    Article  PubMed  CAS  Google Scholar 

  125. Conti Diaz IA, Civila E, Gezuele E, et al. Treatment of human cutaneous sporotrichosis with itraconazole. Mycoses. 1992;35:153–6.

    Article  PubMed  CAS  Google Scholar 

  126. Sharkey-Mathis PK, Kauffman CA, Graybill JR, et al. Treatment of sporotrichosis with itraconazole. NIAID Mycoses Study Group. Am J Med. 1993;95:279–85.

    Article  PubMed  CAS  Google Scholar 

  127. •• de Lima Barros MB, Schubach AO, de Vasconcellos Carvalhaes de Oliveira R, et al. Treatment of cutaneous sporotrichosis with itraconazole–study of 645 patients. Clin Infect Dis. 2011;52(12):e200–6. Large prospective study evaluating the safety and efficacy of itraconazole, most of the patients in the study received itraconazole 100 mg daily with excellent results.

    Article  Google Scholar 

  128. •• Song Y, Zhong SX, Yao L, et al. Efficacy and safety of itraconazole pulses vs. continuous regimen in cutaneous sporotrichosis. J Eur Acad Dermatol Venereol. 2011;25(3):302–5. Small-randomized trial comparing itraconazole pulses vs. continuous regimen in cutaneous sporotrichosis.

    Article  PubMed  CAS  Google Scholar 

  129. Chapman SW, Pappas P, Kauffman C, et al. Comparative evaluation of the efficacy and safety of two doses of terbinafine (500 and 1000 mg day) in the treatment of cutaneous or lymphocutaneous sporotrichosis. Mycoses. 2004;47:62–8.

    Article  PubMed  CAS  Google Scholar 

  130. •• Yamada K, Zaitz C, Framil VM, et al. Cutaneous sporotrichosis treatment with potassium iodide: a 24 year experience in São Paulo State, Brazil. Rev Inst Med Trop Sao Paulo. 2011;53(2):89–93. A retrospective analysis evaluating the safety and efficacy of potassium iodine in the treatment of cutaneous sporotrichosis.

    PubMed  Google Scholar 

  131. •• Xue S, Gu R, Wu T, et al. Oral potassium iodide for the treatment of sporotrichosis. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006136. A cochrane review of the evidence of potassium iodine for the treatment of sporotrichosis.

  132. Francesconi G, Valle AC, Passos S, et al. Terbinafine (250 mg/day): an effective and safe treatment of cutaneous sporotrichosis. J Eur Acad Dermatol Venereol. 2009;23(11):1273–6.

    Article  PubMed  CAS  Google Scholar 

  133. •• Francesconi G, Francesconi do Valle AC, et al. Comparative study of 250 mg/day terbinafine and 100 mg/day itraconazole for the treatment of cutaneous sporotrichosis. Mycopathologia. 2011;171(5):349–54. This study combined with the prior reference suggest that terbinafine 250 mg is an effective option for the treatment of sporotrichosis.

    Article  PubMed  CAS  Google Scholar 

  134. McGinnis MR, Nordoff N, Li RK, et al. Sporothrix schenckii sensitivity to voriconazole, itraconazole and amphotericin B. Med Mycol. 2001;39(4):369–71.

    PubMed  CAS  Google Scholar 

Download references

Disclosure

J. Baddley has been a consultant for Merck, Abbott, and Pfizer. His institution has received grant support from Pfizer. R. La Hoz reported no potential conflicts of interest relevant to this article.

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, 1900 University Boulevard, Tinsley Harrison Tower 229, Birmingham, AL, 35294-0006, USA

    Ricardo M. La Hoz & John W. Baddley

  2. Birmingham Veterans Affairs Medical Center, 700 19th Street South, Birmingham, AL, 35233, USA

    John W. Baddley

Authors
  1. Ricardo M. La Hoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John W. Baddley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John W. Baddley.

Rights and permissions

Reprints and permissions

About this article

Cite this article

La Hoz, R.M., Baddley, J.W. Subcutaneous Fungal Infections. Curr Infect Dis Rep 14, 530–539 (2012). https://doi.org/10.1007/s11908-012-0275-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-012-0275-3

Keywords

Search

Navigation